

研究成果の刊行に関する一覧表

書籍

| 著者氏名 | 論文タイトル名 | 書籍全体の編集者名 | 書籍名 | 出版社名 | 出版地 | 出版年 | ページ |
|--------|--------------------------------------|----------------------------------|---------------------------|------------|-----|------|-----------|
| 関島 良樹 | アミロイドニューロパチー | 福井 次矢, 高木 誠, 小室 一成 | 今日の治療方針 私はこう治療している | 医学書院 | 東京 | 2021 | 1014-1015 |
| 関島 良樹 | RNA 干渉による遺伝性 ATTR アミロイドーシス治療 | 鈴木 則宏, 荒木 信夫, 宇川 義一, 桑原 聡, 塩川 芳昭 | Annual Review 神経 2021 | 中外医学社 | 東京 | 2021 | 302-309 |
| 関島 良樹 | 遺伝性アミロイドーシス | 蒔田 芳男, 櫻井 晃洋 | 臨床遺伝専門医テキスト④各論Ⅲ 臨床遺伝学成人領域 | 株式会社診断と治療社 | 東京 | 2021 | 94-97 |
| 関島 良樹 | 脳アミロイドアンギオパチー | 下畑 享良 | 脳神経内科診断ハンドブック | 中外医学社 | 東京 | 2021 | 37-41 |
| 関島 良樹 | アミロイドーシスによる神経障害 | 下畑 享良 | 脳神経内科診断ハンドブック | 中外医学社 | 東京 | 2021 | 288-292 |
| 小池 春樹 | その他のニューロパチー (糖尿病性, 傍腫瘍性, 薬剤性ニューロパチー) | 永田 栄一郎, 伊藤 義彰 | 脳神経内科学レビュー 2022-'23 | 総合医学社 | 東京 | 2022 | 235-240 |
| 小池 春樹 | 多発ニューロパチー | 福井 次矢, 高木 誠, 小室 一成 | 今日の治療指針 2022 年版 | 医学書院 | 東京 | 2022 | 1009 |
| 小池 春樹 | 免疫介在性ニューロパチーの超微形態学 | 鈴木 則宏, 荒木 信夫, 宇川 義一, 桑原 聡, 塩川 芳昭 | Annual Review 神経 2021 | 中外医学社 | 東京 | 2021 | 294-301 |
| 小池 春樹 | 限局性血管炎に伴う神経障害 | 下畑 享良 | 脳神経内科診断ハンドブック | 中外医学社 | 東京 | 2021 | 559-562 |
| 山田 俊幸 | 臨床検査を使いこなす, 血清タンパク. | 矢富 裕 | 日本医師会雑誌 第150 巻・特別号(1) | 日本医師会 | 東京 | 2021 | 95-101 |
| 小野 賢二郎 | 認知症診療に必要な神経科学の基礎知識. | 山田 正仁 | 認知症診療実践ハンドブック改訂 2 版 | 中外医学社 | 東京 | 2021 | 24-33 |
| 小野 賢二郎 | Alzheimer 病. | 園生 雅弘, 北川 一夫, 青木 正志 | 最新の治療 2021-2023 年 | 南江堂 | 東京 | 2021 | 169-170 |
| 小野 賢二郎 | アルツハイマー病とアミロイドβの現在. | 鈴木 則宏, 荒木 信夫, 宇川 義一, 桑原 聡, 塩川 芳昭 | Annual Review 神経 2021 | 中外医学社 | 東京 | 2021 | 130-136 |

| | | | | | | | |
|-------|---|-----------------------|------------------------|--------------|----|------|---------|
| 北岡 裕章 | 二次性心筋症の鑑別診断へのアプローチ | 北岡 裕章 | 医学のあゆみ 二次性心筋症 | 医歯薬出版株式会社 | 東京 | 2021 | 328-334 |
| 北岡 裕章 | 心筋症の概念 | 北岡 裕章 | 心筋症診療のフロン トライン | 医学書院 | 東京 | 2021 | 6-12 |
| 遠藤 仁 | 心臓アミロイド ーシス | 筒井 裕之 | ザ・ベーシックメソッ ド心不全薬物治療 | メジカルビュー ー | 東京 | 2021 | 209-214 |
| 山本 卓 | 慢性腎臓病に伴う骨・ミネラル代謝異常（血管石灰化、アミロイド骨関節症を含む） | 福井 次矢, 高木 誠, 小室 一成 | 今日の治療指針 2022 年度版 | 医学書院 | 東京 | 2022 | 640-643 |
| 坂井 健二 | 高血圧性以外の脳小血管病: 脳アミロイドアンギオパチー, CADASIL, CARASIL・HDLs. | 山田 正仁 | 認知症診療実践ハンドブック改訂第2版 | 中外医学社 | 東京 | 2021 | 311-325 |

雑誌

| 発表者氏名 | 論文タイトル名 | 発表誌名 | 巻号 | ページ | 出版年 |
|---|--|-------------------------|--------|-----------|------|
| Tateishi Y, Yamada Y, Katsuki M, Nagata T, Yamamoto H, Kohashi K, Koga Y, Hashisako M, Kiyozawa D, Mori T, Kuboyama Y, Kakinokizono A, Miyazaki Y, Yamaguchi A, Tsutsui H, Ninomiya T, Naiki H, Oda Y | Pathological review of cardiac amyloidosis using autopsy cases in a single Japanese institution. | Pathol Res Pract | 227 | 153635 | 2021 |
| Fujimoto T, Yamano T, Miyagawa-Hayashino A, Naiki H, Ueda M, Tasaki M, Yamano M, Zen K, Numata S, Matoba S | Case with transthyretin amyloid cardiomyopathy complicated with rapidly progressive aortic stenosis possibly caused by amyloid deposition in the aortic valve. | Circ Cardiovasc Imaging | 14(11) | e013357 | 2021 |
| Tanaka T, Naito T, Midori Y, Nosaka T, Takahashi K, Ofuji K, Matsuda H, Ohtani M, Hiramatsu K, Imamura Y, Yokoyama O, Naiki H, Nakamoto Y | Gastrointestinal AA amyloidosis secondary to chronic pyelonephritis presenting with refractory diarrhea and severe hypoalbuminemia. | Clin J Gastroenterol | 14(6) | 1642-1648 | 2021 |
| Shintani-Domoto Y, Ishino K, Naiki H, Sakatani T, Ohashi R | Autopsy case with concurrent transthyretin and immunoglobulin amyloidosis. | Pathol Int | 72(1) | 65-71 | 2021 |

| | | | | | |
|--|--|-----------------|------------|---------|------|
| 内木 宏延 | 蓄積病・アミロイドーシス. | 病理と臨床 | 39(臨 増) | 266-269 | 2021 |
| 池田 善彦, 内木 宏延 | 心アミロイドーシス. | 病理と臨床 | 39(10) | 988-992 | 2021 |
| Matsushita H, Isoguchi A, Okada M, Masuda T, Misumi Y, Tsutsui C, Yamaguchi N, Ichiki Y, Sawashita J, Ueda M, Mizuguchi M, Ando Y | Glavonoid, a possible supplement for prevention of ATTR amyloidosis. | Heliyon | 7(10) | e08101 | 2021 |
| Inoue Y, Masuda T, Misumi Y, Ando Y, Ueda M | Metformin attenuates vascular pathology by increasing expression of insulin-degrading enzyme in a mixed model of cerebral amyloid angiopathy and type 2 diabetes mellitus. | Neurosci Lett | 762 | 136136 | 2021 |
| Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM | ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. | Circ Cardiovasc | 14(7) | e000029 | 2021 |
| Tasaki M, Lavatelli F, Obici L, Obayashi K, Miyamoto T, Merlini G, Palladini G, Ando Y, Ueda M | Age-related amyloidosis outside the brain: A state-of-the-art review. | Ageing Res Rev | 70 | 101388 | 2021 |
| Coelho T, Ando Y, Benson MD, Berk JL, Waddington-Cruz M, Dyck PJ, Gillmore JD, Khella SL, Litchy WJ, Obici L, Monteiro C, Tai LJ, Viney NJ, Buchele G, Brambatti M, Jung SW, St L O'Dea L, Tsimikas S, Schneider E, Geary RS, Monia BP, Gertz M | Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-L(Rx) (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy. | Neurol Ther | 10(1) | 375-389 | 2021 |
| Waddington-Cruz M, Wixner J, Amass L, Kiszko J, Chapman D, Ando Y; THAOS | Characteristics of patients with late- vs. early-onset Val30Met transthyretin amyloidosis from the transthyretin amyloidosis outcomes | Neurol Ther | 10(2) | 753-766 | 2021 |

| | | | | | |
|---|---|----------------------|-------|---------|------|
| investigators | survey (THAOS). | | | | |
| Waddington-Cruz M, Ando Y, Amass L, Kiszko J, Chapman D, Sekijima Y; THAOS investigators | Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the transthyretin amyloidosis outcomes survey (THAOS). | J Peripher Nerv Syst | 26(2) | 160-166 | 2021 |
| Inoue Y, Ando Y, Misumi Y, Ueda M | Current management and therapeutic strategies for cerebral amyloid angiopathy. | Int J Mol Sci | 22(8) | 3869 | 2021 |
| 田崎 雅義, 大林 光念, 安東 由喜雄, 植田 光晴 | 新規アミロイド原因蛋白質 EFEMP1 の同定および本分子の疾患との関連 | 臨床化学 | 50(2) | 124-129 | 2021 |
| 安東 由喜雄 | 私の治療「アミロイドーシス」 | 日本医事新報 | 5069 | 41-42 | 2021 |
| Ichimata S, Katoh N, Abe R, Yoshinaga T, Kametani F, Yazaki M, Kusama Y, Sano K, Uehara T, Sekijima Y | Somatostatin-derived amyloid deposition associated with duodenal neuroendocrine tumour (NET): a report of novel localised amyloidosis associated with NET | Amyloid | 29(1) | 64-65 | 2022 |
| Abe R, Katoh N, Takahashi Y, Takasone K, Yoshinaga T, Yazaki M, Kametani F, Sekijima Y | Distribution of amyloidosis subtypes based on tissue biopsy site - Consecutive analysis of 729 patients at a single amyloidosis center in Japan. | Pathol Int | 71(1) | 70-79 | 2021 |
| Aono Y, Hamatani Y, Katoh N, Nakagawa M, Nakamura K, Yazaki M, Kametani F, Iguchi M, Murakami I, Ogawa H, Abe M, Akao M, Sekijima Y | Late-onset Hereditary ATTR Amyloidosis with a Novel p.P63S (P43S) Transthyretin Variant. | Intern Med | 60(4) | 557-561 | 2021 |
| Garcia-Pavia P, Bengel F, Brito D, Damy T, Duca F, Dorbala S, Nativi-Nicolau J, Obici L, Rapezzi C, Sekijima Y, Elliott PM | Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. | Eur J Heart Fail | 23(6) | 895-905 | 2021 |
| Ichimata S, Katoh N, Abe R, Yoshinaga T, Kametani F, Yazaki M, Uehara T, Sekijima Y | A case of novel amyloidosis: glucagon-derived amyloid deposition associated with pancreatic neuroendocrine tumour. | Amyloid | 28(1) | 72-73 | 2021 |
| Yanagisawa S, Takahashi Y, Sasaki J, Takasone K, Yoshie K, Koyama J, Katoh N, Yazaki M, Kuwahara K, Sekijima Y | Absolute quantitative analysis of cardiac amyloidosis using SPECT/CT with 99mTc-pyrophosphate. | Amyloid | 28(3) | 213-214 | 2021 |

| | | | | | |
|--|--|-----------------------|--------|-----------|------|
| 関島 良樹 | 遺伝性 ATTR アミロイドーシス | Pharma Medica | 39(3) | 39-43 | 2021 |
| 関島 良樹 | アミロイドーシス治療の進歩 | 日本内科学会雑誌 | 110(6) | 1170-1177 | 2021 |
| 関島 良樹 | ATTR アミロイドーシスは決してめずらしい病気ではない | 内科 | 128(3) | 617-619 | 2021 |
| 関島 良樹 | アミロイドニューロパチー | CLINICAL NEUROSCIENCE | 39(11) | 1444-1446 | 2021 |
| 中村 勝哉, 関島 良樹 | 遺伝性神経疾患の遺伝カウンセリングと発症前診断 | 臨床神経学 | 61(9) | 588-593 | 2021 |
| Ueda M | Transthyretin: its function and amyloid formation. | Neurochem Int | 155 | 105313 | 2022 |
| Inomata T, Tahara N, Nakamura K, Endo J, Ueda M, Ishii T, Kitano Y, Koyama J | Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm. | ESC Heart Fail | 8 | 2647-2659 | 2021 |
| Yumoto S, Doi K, Higashi T, Shimao Y, Ueda M, Ishihara A, Adachi Y, Ishiodori H, Honda S, Baba H | Intra-abdominal bleeding caused by amyloid transthyretin amyloidosis in the gastrointestinal tract: a case report. | Clin J Gastroenterol | 15 | 140-145 | 2022 |
| Tasaki M, Oishi T, Ueda M | EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) amyloid deposits in the lower rectum from aged patient with bloody stools. | Pathol Int | 72(3) | 217-218 | 2022 |
| Benson MD, Berk JL, Dispenzieri A, Damy T, Gillmore JD, Hazenberg BP, Lavatelli F, Picken MM, Röcken C, Schönland S, Ueda M, Westermark P | Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. | Amyloid | 29 | 8-13 | 2022 |
| Takashio S, Yamada T, Nishi M, Morioka M, Nakashima N, Hirakawa K, Hanatani S, Usuku H, Yamamoto E, Ueda M, Matsushita K, Kaikita K, Tsujita K | Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy. | J Cardiol | 79 | 50-57 | 2022 |

| | | | | | |
|---|--|-----------------|-----|-----------|------|
| Nakashima N, Takashio S, Morioka M, Nishi M, Hirakawa K, Hanatani S, Masuda T, Ueda M, Tsujita K | Preclinical diagnosis of wild-type transthyretin amyloid cardiomyopathy in a patient undergoing carpal tunnel release. | J Cardiol Cases | 24 | 250-253 | 2021 |
| Oike F, Usuku H, Yamamoto E, Yamada T, Egashira K, Morioka M, Nishi M, Komorita T, Hirakawa K, Tabata N, Yamanaga K, Fujisue K, Hanatani S, Sueta D, Arima Y, Araki S, Takashio S, Oda S, Misumi Y, Kawano H, Matsushita K, Ueda M, Matsui H, Tsujita K | Prognostic value of left atrial strain in patients with wild-type transthyretin amyloid cardiomyopathy. | ESC Heart Fail | 8 | 5316-5326 | 2021 |
| Maeda K, Kubota Y, Kitagawa S, Ueda M, Ando Y, Ito Y | The prostate as a good candidate organ for proving amyloid deposition in non-endemic late onset hereditary transthyretin amyloidosis: Report of two cases. | J Neurol Sci | 424 | 117418 | 2021 |
| Ohya Y, Tasaki M, Hayashida S, Katayama N, Tsuchida T, Kuriwaki K, Ueda M, Inomata Y | Carpal tunnel syndrome due to iatrogenic amyloidosis after domino liver transplantation from hereditary transthyretin amyloidosis: a case report. | Transplant Proc | 53 | 1313-1316 | 2021 |
| Okada M, Misumi Y, Masuda T, Takashio S, Tasaki M, Matsushita H, Ueda A, Inoue Y, Nomura T, Nakajima M, Yamashita T, Shinriki S, Matsui H, Tsujita K, Ando Y, Ueda M | Plasma growth differentiation factor 15: A novel tool to detect early changes of hereditary transthyretin amyloidosis. | ESC Heart Fail | 8 | 1178-1185 | 2021 |
| Tasaki M, Okada M, Yanagisawa A, Nomura T, Ueda A, Inoue Y, Masuda T, Misumi Y, Yamashita T, Miyamoto T, Obayashi K, Ando Y, Ueda M | Apolipoprotein AI amyloid deposits in the ligamentum flavum in patients with lumbar spinal canal stenosis. | Amyloid | 28 | 107-112 | 2021 |
| Tsukamoto Y, Tasaki M, Fujii H, Tsujie M, Ueda M | EGF-containing fibulin-like extracellular matrix protein 1 amyloid incidentally found in surgically resected specimens of colon cancer: a case report emphasizing on an unrecognized type. | Amyloid | 28 | 136-137 | 2021 |
| Adams D, Polydefkis M, Gonzalez-Duarte A, Wixner J, Kristen A, Schmidt H, Berk J, López I, Dispenzieri A, Conceição I, Slama M, Gillmore J, Kyriakides T, | Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. | Lancet Neurol | 20 | 49-59 | 2021 |

| | | | | | |
|---|---|----------------|--------|---------|------|
| Ajrout-Driss S, Waddington-Cruz M, Mezei M, Plante-Bordeneuve V, Attarian S, Mauricio E, Brannagan T, Ueda M, Aldinc E, Wang J, White M, Vest J, Berber E, Sweetser M, Coelho T | | | | | |
| Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schechter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators | Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. | N Engl J Med | 385 | 46-58 | 2021 |
| Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida SI, Shibayama H, Matsuda M, Shimazu Y, Adachi Y, Kosugi S, Uchiyama H, Tanaka H, Hanamoto H, Shimura Y, Kanda J, Onda Y, Uoshima N, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S | Outcomes of ixazomib/lenalidomide/dexamethason e for multiple myeloma: A multicenter retrospective analysis. | Eur J Haematol | 106(4) | 555-562 | 2021 |
| Takakuwa T, Ohta K, Nakatani E, Ito T, Kaneko H, Fuchida SI, Shimura Y, Yagi H, | Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma. | Hematol Oncol | 39(3) | 349-357 | 2021 |

| | | | | | |
|---|---|----------------------|-----|-----------|------|
| Shibayama H, Kanda J, Uchiyama H, Kosugi S, Tanaka H, Kawata E, Uoshima N, Ishikawa J, Shibano M, Karasuno T, Shindo M, Shimizu Y, Imada K, Kanakura Y, Kuroda J, Hino M, Nomura S, Takaori-Kondo A, Shimazaki C, Matsumura I | | | | | |
| Kawaji-Kanayama Y, Kobayashi T, Muramatsu A, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida SI, Shimazaki C, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Shimura Y, Horiike S, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators | Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients. | Cancer Rep (Hoboken) | 14 | e1476 | 2021 |
| Nakaya A, Shibayama H, Nakatani E, Shimura Y, Kosugi S, Tanaka H, Fuchida S, Kanda J, Uoshima N, Kaneko H, Imada K, Ohta K, Ito T, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S | Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum. | eJHem | 2 | 765-773 | 2021 |
| Katsuragawa-Taminishi Y, Ide D, Maegawa-Matsui S, Fuchida S, Hatsuse M, Murakami S, Kuroda J, Shimazaki C | Acquired amegakaryocytic thrombocytopenic purpura that presented as cyclic thrombocytopenia associated with anti-phospholipid antibody syndrome. | Clin Hematol Res | 4 | 42-46 | 2021 |
| Iida S, Ishikawa T, Min CK, Kim K, Yeh SP, Usmani SZ, Mateos M-V, Nahi H, Hueck C, Qin X, Parasrampur DA, Gries KS, Qi M, Bahlis N, Ito S | Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study. | Ann Hematol | 100 | 1065-1077 | 2021 |
| Iida S, Izumi T, Komeno T, Terui Y, Chou T, Ikeda T, Berg D, Fukunaga S, Sugiura K, Sasaki M | A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or | Int J Clin Oncol | 27 | 224-233 | 2021 |

| | | | | | |
|--|---|------------------|-------|-----------|------|
| | refractory multiple myeloma. | | | | |
| Ri M, Iida S, Maruyama D, Sakabe A, Kamei R, Nakashima T, Tohkn M, Osaga S, Tobinai K, Fukuhara N, Miyazaki K, Tsukamoto N, Tsujimura H, Yoshimitsu M, Miyamoto K, Tsukasaki K, Nagai H | HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1). | Cancer Sci | 112 | 5011-5019 | 2021 |
| Avet-Loiseau H, San-Miguel J, Casneuf T, Iida S, Lonial S, Usmani SZ, Spencer A, Moreau P, Plesner T, Weisel K, Ukropec J, Chiu C, Trivedi S, Amin H, Krevvata M, Ramaswami P, Qin X, Qi M, Sun S, Qi M, Kobos R, Bahlis NJ | Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed/refractory multiple myeloma: analysis of POLLUX and CASTOR. | J Clin Oncol | 39 | 1139-1149 | 2021 |
| Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, Paiva B, Bahlis NJ, Plesner T, Hungria V, Moreau P, Mateos M-V, Perrot A, Iida S, Facon T, Kumar S, van de Donk NWCJ, Sonneveld P, Spencer A, Krevvata M, Heuck C, Wang J, Ukropec J, Kobos R, Sun S, Qi M, Munshi N | Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA. | Blood | 139 | 835-844 | 2022 |
| Suzuki N, Okuyama T, Akechi T, Kusumoto S, Ri M, Inagaki A, Kayukawa S, Yano H, Yoshida T, Shiraga K, Hashimoto H, Aiki S, Iida S | Symptoms and health-related quality of life in patients with newly diagnosed multiple myeloma: a multicenter prospective cohort study. | Jpn J Clin Oncol | 52 | 163-169 | 2022 |
| 飯田 真介 | 分子標的薬による MGRS の治療 | 腎と透析 | 92(2) | 463-466 | 2022 |
| Koike H, Nishi R, Ohyama K, Morozumi S, Kawagashira Y, Furukawa S, Mouri N, Fukami Y, Iijima M, Sobue G, Katsuno M | ANCA-associated vasculitic neuropathies: a review. | Neurol Ther | 11(1) | 21-38 | 2022 |

| | | | | | |
|--|--|--------------------------|------------|----------|------|
| Koike H, Katsuno M | Paraproteinemia and neuropathy. | Neurol Sci | 42(11) | 4489-501 | 2021 |
| Koike H, Iguchi Y, Sahashi K, Katsuno M | Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment. | Molecules | 26(16) | 5091 | 2021 |
| Koike H, Katsuno M | The Ultrastructure of Tissue Damage by Amyloid Fibrils. | Molecules | 26(15) | 4611 | 2021 |
| Koike H, Katsuno M | The role of macrophages in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. | Neurol Clin Neurosci | 9(3) | 203-10 | 2021 |
| Koike H, Chiba A, Katsuno M | Emerging Infection, Vaccination, and Guillain-Barré Syndrome: A Review. | Neurol Ther | 10(2) | 523-37 | 2021 |
| Koike H, Okumura T, Murohara T, Katsuno M | Multidisciplinary Approaches for Transthyretin Amyloidosis. | Cardiol Ther | 10(2) | 289-311 | 2021 |
| Koike H, Katsuno M | Macrophages and Autoantibodies in Demyelinating Diseases. | Cells | 10(4) | 844 | 2021 |
| Hsueh HW, Chao CC, Chang K, Jeng YM, Katsuno M, Koike H, Hsieh ST | Unique Phenotypes With Corresponding Pathology in Late-Onset Hereditary Transthyretin Amyloidosis of A97S vs. V30M. | Front Aging Neurosci | 13 | 786322 | 2021 |
| Jozuka R, Kimura H, Uematsu T, Fujigaki H, Yamamoto Y, Kobayashi M, Kawabata K, Koike H, Inada T, Saito K, Katsuno M, Ozaki N | Severe and long-lasting neuropsychiatric symptoms after mild respiratory symptoms caused by COVID-19: A case report. | Neuropsychopharmacol Rep | 42(1) | 114-119 | 2022 |
| Sommer C, Carroll AS, Koike H, Katsuno M, Ort N, Sobue G, Vucic S, Spies JM, Doppler K, Kiernan MC | Nerve biopsy in acquired neuropathies. | J Peripher Nerv Syst | 26 Suppl 2 | S21-S41 | 2021 |
| Oishi M, Mukaino A, Kunii M, Saito A, Arita Y, Koike H, Higuchi O, Maeda Y, Abiru N, Yamaguchi N, Kawano H, Tsuiki E, Tanaka T, Matsuo H, Katsuno M, Tanaka F, Tsujino A, Nakane S | Association between neurosarcoidosis with autonomic dysfunction and anti-ganglionic acetylcholine receptor antibodies. | J Neurol | 268(11) | 4265-79 | 2021 |

| | | | | | |
|--|--|-------------------------------|---------|---------------|------|
| Fukami Y, Iijima M, Koike H, Yamada S, Hashizume A, Katsuno M | Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients. | J Neurol | 268(10) | 3835-44 | 2021 |
| Yamada S, Hashizume A, Hijikata Y, Ito D, Kishimoto Y, Iida M, Koike H, Hirakawa A, Katsuno M | Ratio of urinary N-terminal titin fragment to urinary creatinine is a novel biomarker for amyotrophic lateral sclerosis. | J Neurol Neurosurg Psychiatry | 92(10) | 1072-9 | 2021 |
| Ando T, Nakamura R, Kuru S, Yokoi D, Atsuta N, Koike H, Suzuki M, Hara K, Iguchi Y, Harada Y, Yoshida Y, Hattori M, Murakami A, Noda S, Kimura S, Sone J, Nakamura T, Goto Y, Mano K, Okada H, Okuda S, Nishino I, Ogi T, Sobue G, Katsuno M | The wide-ranging clinical and genetic features in Japanese families with valosin-containing protein proteinopathy. | Neurobiol Aging | 100 | 120.e1-120.e6 | 2021 |
| 小池 春樹 | ANCA 関連血管炎における末梢神経病変 | リウマチ科 | 66(6) | 608-614 | 2021 |
| 小池 春樹 | 全身性疾患における神経障害 | Clinical Neuroscience | 39(10) | 1286-1290 | 2021 |
| 小池 春樹 | 自己免疫性自律神経ニューロパチーの臨床像と治療法 | 脳神経内科 | 95(2) | 172-176 | 2021 |
| 小池 春樹 | 純粋自律神経不全症型のレビー小体病と免疫介在性自律神経ニューロパチー | 自律神経 | 58(2) | 199-203 | 2021 |
| 仁紫 了爾, 小池 春樹, 勝野 雅央 | 好酸球性多発血管炎性肉芽腫症に伴う末梢神経障害 | 末梢神経 | 32(1) | 68-74 | 2021 |
| 望月 秀樹, 青木 正志, 池中建介, 井上 治久, 岩坪 威, 宇川 義一, 岡澤 均, 小野 賢二郎, 小野 寺理, 北川 一夫, 齊藤 祐子, 下畑 享良, 高橋 良輔, 戸田 達史, 中原 仁, 松本 理器, 水澤 英洋, 三井 純, 村山 繁雄, 勝野 雅央, 青木 吉嗣, 石浦 浩之, 和泉 唯信, 小池 春樹, 島田 斉, 高橋 祐二, | 脳神経疾患克服に向けた研究推進の提言2020、総論 | 臨床神経学 | 61(11) | 709-721 | 2021 |

| | | | | | |
|--|--|-------------------|--------|---------|------|
| 徳田 隆彦, 中嶋 秀人, 波田 野琢, 三澤 園子, 渡辺 宏久, 水澤 英洋, 阿部 康二, 宇川 義一, 梶龍 兒, 亀井 聡, 神田 隆, 吉良 潤一, 楠 進, 鈴木 則宏, 祖父江 元, 高橋 良輔, 辻 省次, 中島 健二, 西澤 正豊, 服部 信孝, 福山 秀直, 峰松 一夫, 村山 繁雄, 望月 秀樹, 山田 正仁, 日本神経学会将来構想委員会 | | | | | |
| Fujii H, Kono K, Goto S, Watanabe K, Nishii T, Kono A, Nishi S | Evaluation of Aortic Calcification Using a Three-Dimensional Volume-Rendering Method in Patients with Chronic Kidney Disease. | J Bone Miner Meta | 39(3) | 439-445 | 2021 |
| 西 慎一 | 指定難病 アミロイドーシスに対する対策. | 腎臓内科 | 13(1) | 77-85 | 2021 |
| Mizuno H, Hoshino J, So M, Kogure Y, Fujii T, Ubara Y, Takaichi K, Nakaniwa T, Tanaka H, Kurisu G, Kametani F, Nakagawa M, Yoshinaga T, Sekijima Y, Higuchi K, Goto Y, Yazaki M | Dialysis-related amyloidosis associated with a novel β 2-microglobulin variant. | Amyloid | 28(1) | 42-49 | 2021 |
| Hoshino J, Tsunoda R, Nagai K, Kai H, Saito C, Ito Y, Asahi K, Kondo M, Iseki K, Iseki C, Okada H, Kashihara N, Narita I, Wada T, Combe C, Pisoni RL, Robinson BM, Yamagata K | Comparison of annual eGFR decline among primary kidney diseases in patients with CKD G3b-5: results from a REACH-J CKD cohort study. | Clin Exp Nephrol | 25(8) | 902-910 | 2021 |
| Hatano M, Kitajima I, Yamamoto S, Nakamura M, Isawa K, Suwabe T, Hoshino J, Sawa N, Ubara Y | Dialysis-related carpal tunnel syndrome in the past 40 years. | Clin Exp Nephrol | 26(1) | 68-74 | 2022 |
| Fukuda M, Sawa N, Hoshino J, Ohashi K, Motoaki M, Ubara Y | Tocilizumab preserves renal function in rheumatoid arthritis with AA amyloidosis and end-stage kidney disease: Two case reports. | Clin Nephrol | 95(1) | 54-61 | 2021 |
| 花房 規男, 阿部 雅紀, 常喜 信彦, 星野 純一, 菊池 勘, 後藤 俊介, 神田 英一郎, 谷口 正智, 中井 滋, 長沼 俊秀, 長谷川 毅, 三浦 健一郎, 和田 篤志, 武 | わが国の慢性透析療法の現況 (2020年12月31日現在) | 透析会誌 | 54(12) | 611-657 | 2021 |

| | | | | | |
|--|---|-------------------------|-----|-----------|------|
| 本 佳昭 | | | | | |
| Kamei R, Sawahata M, Yoshizumi N, Sata M, Nakayama M, Yamada T, Taniguchi N, Suzuki T, Bando M, Hagiwara K | Pulmonary mycobacterium avium complex disease complicated by cancer: an 11-year survey at a single center. | J Rural Med | 16 | 72-76 | 2021 |
| Futamura A, Hieda S, Mori Y, Sugimoto A, Kasai H, Kuroda T, Yano S, Kasuga K, Murakami H, Ikeuchi T, Ono K | Cingulate Island Sign in Single Photon Emission Computed Tomography: Clinical Biomarker Correlations in Lewy Body Disease and Alzheimer's Disease. | J Alzheimers Dis | 79 | 1003-1008 | 2021 |
| Futamura A, Hieda S, Mori Y, Kasuga K, Sugimoto A, Kasai H, Kuroda T, Yano S, Tsuji M, Ikeuchi T, Irie K, Ono K | Toxic amyloid- β_{42} conformer may accelerate the onset of Alzheimer's disease in the preclinical stage. | J Alzheimers Dis | 80 | 639-646 | 2021 |
| Hamaguchi T, Kim JH, Hasegawa A, Goto R, Sakai K, Ono K, Itoh Y, Yamada M | Exogenous A β seeds induce A β depositions in the blood vessels rather than the brain parenchyma, independently of A β strain-specific information. | Acta Neuropathol Commun | 9 | 151 | 2021 |
| Ibrahim NF, Hamezah HS, Yanagisawa D, Tsuji M, Kiuchi Y, Ono K, Tooyama I | The effect of α -tocopherol, α - and γ -tocotrienols on amyloid- β aggregation and disaggregation in vitro. | Biochem Biophys Rep | 28 | 101131 | 2021 |
| Kimura A, Tsuji M, Yasumoto T, Mori Y, Oguchi T, Tsuji Y, Umino M, Umino A, Nishikawa T, Nakamura S, Inoue T, Yamada M, Teplow DB, Kiuchi Y, Ono K | Myricetin prevents high molecular weight A β_{1-42} oligomer-induced neurotoxicity through antioxidant effects in cell membranes and mitochondria. | Free Radic Biol Med | 171 | 232-244 | 2021 |
| Kuroda T, Honma M, Mori Y, Futamura A, Sugimoto A, Kasai H, Yano S, Hieda S, Kasuga K, Ikeuchi T, Ono K | White Matter Lesions May Aid in Differentiating Idiopathic Normal Pressure Hydrocephalus and Alzheimer's Disease. | J Alzheimers Dis | 85 | 851-862 | 2022 |
| Mori Y, Tsuji M, Oguchi T, Kasuga K, Kimura A, Futamura A, Sugimoto A, Kasai H, Kuroda T, Yano S, Hieda S, Kiuchi Y, Ikeuchi T, Ono K | Serum BDNF as a Potential Biomarker of Alzheimer's Disease: Verification Through Assessment of Serum, Cerebrospinal Fluid, and Medial Temporal Lobe Atrophy. | Front Neurol | 12 | 653267 | 2021 |
| Nakano H, Hamaguchi T, Ikeda T, Watanabe-Nakayama T, Ono K, Yamada M | Inactivation of seeding activity of amyloid β -protein aggregates in vitro. | J Neurochem | 160 | 499-516 | 2022 |
| Sakai K, Noguchi-Shinohara M, Ikeda T, Hamaguchi T, Ono K, Yamada M | Cerebrospinal fluid cytokines and metalloproteinases in cerebral amyloid angiopathy-related inflammation. | Acta Neurol Scand | 143 | 450-457 | 2021 |

| | | | | | |
|---|---|-----------------------|--------|---------|------|
| Senda M, Ishii K, Ito K, Ikeuchi T, Matsuda H, Iwatsubo T, Iwata A, Ihara R, Suzuki K, Kasuga K, Ikari Y, Niimi Y, Arai H, Tamaoka A, Arahata Y, Itoh Y, Tachibana H, Ichimiya Y, Washizuka S, Odawara T, Ishii K, Ono K, Yokota T, Nakanishi A, Matsubara E, Mori H, Shimada H | A Japanese Multicenter Study on PET and Other Biomarkers for Subjects with Potential Preclinical and Prodromal Alzheimer's Disease. | J Prev Alzheimers Dis | 8 | 495-502 | 2021 |
| Ono K, Watanabe-Nakayama T | Aggregation and structure of amyloid β -protein. | Neurochem Int | 151 | 105208 | 2021 |
| Watanabe-Nakayama T, Ono K | Acquisition and processing of high-speed atomic force microscopy videos for single amyloid aggregate observation. | Methods | 197 | 4-12 | 2022 |
| 小野 賢二郎 | アルツハイマー病の病態と治療戦略を考える. | 老年期認知症研究会誌 | 23 | 41-42 | 2021 |
| 小野 賢二郎 | 認知症診療の知 アルツハイマー病の疾患修飾療法の展望. | 脳神経外科ジャーナル | 30 | 840-844 | 2021 |
| 小野 賢二郎 | 認知症診療の現状と将来展望：A β を中心とするアプローチ. | 神経治療学 | 38 | 343-346 | 2021 |
| 小野 賢二郎 | 認知症の Patient Journey を見つけた医療介入. | 老年精神医学雑誌 | 32 増刊号 | 19-25 | 2022 |
| 杉本 あずさ, 小野 賢二郎 | 神経内科学のトピックス A β 凝集制御薬. | 認知症の最新医療 | 11 | 18-23 | 2021 |
| 稗田 宗太郎, 小野 賢二郎 | 神経内科学のトピックス A β 免疫療法時代における高齢者タウオパチーの重要性. | 認知症の最新医療 | 11 | 38-40 | 2021 |
| 稗田 宗太郎, 小野 賢二郎 | 認知症の治療の進歩. | 神経治療学 | 38 | 343-346 | 2021 |
| Takahashi M, Okamoto N, Nishida K, Nakaoka Y, Imai RI, Seki SI, Kubo T, Yamasaki N, Kitaoka H, Kubokawa SI, Kawai K, Hamashige N, Doi Y | Progressive deterioration of frailty is associated with poor outcomes in patients with transthyretin cardiac amyloidosis. | Geriatr Gerontol Int | 21 | 967-969 | 2021 |

| | | | | | |
|---|--|----------------------|--------|-----------|------|
| Ochi Y, Kubo T, Baba Y, Sugiura K, Ueda M, Miyagawa K, Noguchi T, Hirota T, Hamada T, Yamasaki N, Kitaoka H | Wild-Type Transthyretin Amyloidosis in Female Patients - Consideration of Sex Differences. | Cir rep | 3(8) | 465-471 | 2021 |
| Sugiura K, Kozuki H, Ueba H, Kubo T, Ochi Y, Baba Y, Miyagawa K, Noguchi T, Hirota T, Yamasaki N, Wada N, Nakashima J, Murakami I, Ikeuchi M, Kitaoka H | Tenosynovial and Cardiac Transthyretin Amyloidosis in Japanese Patients Undergoing Carpal Tunnel Release. | Cir rep | 3(6) | 338-344 | 2021 |
| 中屋 雄太, 大木本 明義, 北岡 裕章 | 心アミロイドーシス患者の心肺運動負荷試験指標の特徴に関する実態調査 | 心臓 | 54(1) | 51-57 | 2021 |
| 北岡 裕章 | 高齢者心不全と心アミロイドーシス. | 老年内科 | 4(1) | 57-64 | 2021 |
| Tahara N, Lairez O, Endo J, Okada A, Ueda M, Ishii T, Kitano Y, Lee HE, Russo E, Kubo T | ^{99m} Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy. | ESC Heart Fail | 9(1) | 1251-262 | 2022 |
| Tahara N, Tahara A, Maeda S, Yoshimura H, Bekki M, Sugiyama Y, Honda A, Igata S, Nishino Y, Matsui T, Fukami A, Enomoto M, Adachi H, Fukumoto Y, Yamagishi SI | Increased urinary levels of pentosidine measured by a newly developed ELISA are independently correlated with fracture after fall. | Rejuvenation Res | 24(6) | 449-455 | 2021 |
| Kawaguchi T, Honda A, Sugiyama Y, Nakano D, Tsutsumi T, Tahara N, Torimura T, Fukumoto Y | Association between the albumin-bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A data-mining analysis. | Hepatol Res | 51(12) | 1207-1218 | 2021 |
| Sugiyama Y, Tahara N, Ueno T, Fukumoto Y | First remote-controlled robotic-enhanced balloon pulmonary angioplasty to chronic thromboembolic pulmonary hypertension. | Eur Heart J Case Rep | 5(10) | ytab404 | 2021 |
| Bekki M, Tahara N, Tahara A, Maeda-Ogata S, Sugiyama Y, Honda A, Igata S, Harada A, Hirakawa Y, Kurata S, Fujimoto K, Abe T, Fukumoto Y, Ueno T | Switching from clopidogrel to prasugrel resolves vascular inflammation in patients receiving long-term aspirin plus clopidogrel therapy after coronary stent implantation. | J Nucl Cardiol | 28(3): | 1191-1192 | 2021 |
| Honda A, Tahara N, Shojima T, Fukumoto Y | Multimodal imaging of quadricuspid aortic valve in elderly patient. | Eur Heart J Case Rep | 5(9) | ytab344 | 2021 |

| | | | | | |
|--|---|--------------------------------|---------|-----------|------|
| 田原 宣広 | 炎症と動脈硬化 | 久留米醫學會雜誌 | 84(6・7) | 205-217 | 2021 |
| Moriyama H, Kitakata H, Endo J, Ikura H, Fukuda K | Early Diagnosis of Amyloid Cardiomyopathy: Potential and Need Before the Onset of Decompensated Heart Failure. | JACC CardioOncol | 3(2) | 338 | 2021 |
| Kitakata H, Endo J, Matsushima H, Yamamoto S, Ikura H, Hirai A, Koh S, Ichihara G, Hiraide T, Moriyama H, Shirakawa K, Goto S, Katsumata Y, Anzai A, Kataoka M, Tokuyama T, Ishido S, Yanagi S, Fukuda K, Sano M | MITOL/MARCH5 determines the susceptibility of cardiomyocytes to doxorubicin-induced ferroptosis by regulating GSH homeostasis. | J Mol Cell Cardiol | 161 | 116-129 | 2021 |
| Kitakata H, Endo J, Hashimoto S, Mizuno E, Moriyama H, Shirakawa K, Goto S, Katsumata Y, Fukuda K, Sano M | Imeglimin prevents heart failure with preserved ejection fraction by recovering the impaired unfolded protein response in mice subjected to cardiometabolic stress. | Biochem Biophys Res Commun | 572 | 185-190 | 2021 |
| Goto S, Mahara K, Beussink-Nelson L, Ikura H, Katsumata Y, Endo J, Gaggin HK, Shah SJ, Itabashi Y, MacRae CA, Deo RC | Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. | Nat Commun | 12(1) | 2726 | 2021 |
| Miura K, Kimura M, Anzai A, Arai T, Kawakami T, Yuasa S, Hayashida K, Endo J, Tsuruta H, Itabashi Y, Kawamura A, Fukuda K, Kanazawa H | Predictors of New-Onset Atrial Tachyarrhythmias After Transcatheter Atrial Septal Defect Closure in Adults. | Heart Lung Circ | 30(9) | 1406-1413 | 2021 |
| Sugiyama Y, Hakuno D, Yonemori K, Endo J, Sueyoshi K | Paraneoplastic rheumatic syndrome caused by left ventricular intimal sarcoma. | Eur Heart J Cardiovasc Imaging | 22(4) | e9 | 2021 |
| Goto S, Ichihara G, Katsumata Y, Ko S, Anzai A, Shirakawa K, Endo J, Kataoka M, Moriyama H, Hiraide T, Kitakata H, Kobayashi T, Fukuda K, Sano M | Time-Series Transcriptome Analysis Reveals the miR-27a-5p-Ppm1l Axis as a New Pathway Regulating Macrophage Alternative Polarization After Myocardial Infarction. | Circ J | 85(6) | 929-938 | 2021 |
| Shinya Y, Hiraide T, Momoi M, Goto S, Suzuki H, Katsumata Y, Kurebayashi Y, Endo J, Sano M, Fukuda K, Kosaki K, Kataoka M | TNFRSF13B c.226G>A (p.Gly76Ser) as a Novel Causative Mutation for Pulmonary Arterial Hypertension. | J Am Heart Assoc | 10(5) | e019245 | 2021 |

| | | | | | |
|---|--|--------------------------|--------|-----------|------|
| Murata M, Kawakami T, Kataoka M, Moriyama H, Hiraide T, Kimura M, Endo J, Kohno T, Itabashi Y, Fukuda K | Clinical Significance of Guanylate Cyclase Stimulator, Riociguat, on Right Ventricular Functional Improvement in Patients with Pulmonary Hypertension. | Cardiolog | 146(1) | 130-136 | 2021 |
| Kitakata H, Itabashi Y, Kanazawa H, Miura K, Kimura M, Shinada K, de Jongh MC, Endo J, Tsuruta H, Murata M, Kawamura A, Murata M, Fukuda K | Appropriate device selection for transcatheter atrial septal defect closure using three-dimensional transesophageal echocardiography. | Int J Cardiovasc Imaging | 37(4) | 1159-1168 | 2021 |
| 遠藤 仁 | 心アミロイドーシスの最新の治療 | 医学のあゆみ | 277(5) | 45-50 | 2021 |
| Fukuda M, Sawa N, Hoshino J, Ohashi K, Motoaki M, Ubara Y | Tocilizumab preserves renal function in rheumatoid arthritis with AA amyloidosis and end-stage kidney disease: Two case reports. | Clin Nephrol | 95(1) | 54-61 | 2021 |
| 大橋 健一 | アミロイドーシスの病理診断 | 診断病理 | 38(3) | 226-239 | 2021 |
| Harada T, Hiasa M, Teramachi J, Abe M | Myeloma-Bone Interaction: A Vicious Cycle via TAK1-PIM2 Signaling. | Cancers | 13(17) | 4441 | 2021 |
| Hiasa M, Harada T, Eiji Tanaka, Abe M | Pathogenesis and treatment of multiple myeloma bone disease. | Jpn Dent Sci Rev | 57 | 164-173 | 2021 |
| Sumitani R, Hori T, Murai J, Kawata S, Oura M, Sogabe K, Takahashi M, Harada T, Fujii S, Miki H, Kagawa K, Abe M, Nakamura S | Acute Myeloid Leukemia Developing with Acute Pancreatitis Mimicking Autoimmune Pancreatitis. | Intern Med | 60(11) | 1753-1757 | 2021 |
| Takashi Y, Sawatsubashi S, Endo I, Ohnishi Y, Abe M, Matsuhisa M, Kawanami D, Matsumoto T, Fukumoto S | Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life span. | Biochem Biophys Rep | 27 | 101107 | 2021 |
| Tanimoto K, Hiasa M, Tenshin H, Teramachi J, Oda A, Harada T, Higa Y, Sogabe K, Oura M, Sumitani R, Hara T, Itsuro Endo, Matsumoto T, Tanaka E, Abe M | Mechanical unloading aggravates bone destruction and tumor expansion in myeloma. | Haematologica | 107(3) | 744-49 | 2021 |
| Tenshin H, Teramachi J, Ashtar M, Hiasa M, Inoue Y, Oda A, Tanimoto K, Shimizu S, | TGF- β -activated kinase-1 inhibitor LL-Z1640-2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis | Clin Transl Immunology | 11(1) | e1371 | 2022 |

| | | | | | |
|---|---|----------------------|-------------|-----------|------|
| Higa Y, Harada T, Oura M, Sogabe K, Hara T, Sumitani R, Maruhashi T, Sebe M, Tsutsumi R, Sakaue H, Endo I, Matsumoto T, Tanaka E, Abe M | by inhibiting NLRP3 inflammasome, TACE, TNF- α and RANKL expression. | | | | |
| Takei M, Okada N, Nakamura S, Kagawa K, Fujii S, Miki H, Ishizawa K, Abe M, Sato Y | A Genome-Wide Association Study Predicts the Onset of Dysgeusia Due to Anti-cancer Drug Treatment. | Biol Pharm Bull | 45(1) | 114-117 | 2022 |
| Fuchida S, Kawamura K, Sunami K, Tsukada N, Fujii S, Ohkawara H, Usuki K, Wake A, Endo S, Ishiyama K, Ueda Y, Nakamura Y, Miyamoto T, Fukuda T, Ichinohe T, Atsuta Y, Takamatsu H | Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation. | Transplant Cell Ther | 28(2) | 76-82 | 2022 |
| Kastritis E, Palladini G, Minnema MC, Suzuki K, Bensinger W et al. | Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. | N Engl J Med | 385(1) | 46-58 | 2021 |
| Moreau P, Dimopoulos MA, Suzuki K, Risse ML, Martin T, et al. | Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. | Lancet | 397 (10292) | 2361-2371 | 2021 |
| Knop S, Mateos MV, Dimopoulos MA, Suzuki K, Cavo M, et al. | Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. | BMC Cancer | 21(1) | 659 | 2021 |
| Quach H, Nooka A, Samoylova O, Suzuki K, Mateos MV, et al. | Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. | Br J Haematol | 194(4) | 784-788 | 2021 |
| Hosen N, Yoshihara S, Suzuki K, Iida S, et al. | Expression of activated integrin $\beta 7$ in multiple myeloma patients. | Int J Hepatol | 114(1) | 3-7 | 2021 |
| Matsumoto M, Suzuki K, Kuroda J, Iida S, et al. | Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients. | Int J Hematol | 113(6) | 777-784 | 2021 |
| Plesner T, Dimopoulos MA, Suzuki K, Gries KS, et al. | Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. | Br J Haematol | 194(1) | 132-139 | 2021 |

| | | | | | |
|---|--|----------------------------|----------|-----------|------|
| Facon T, Venner CP, Suzuki K, RajkumarSV, et al. | Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. | Blood | 137(26) | 3616-3628 | 2021 |
| Suzuki K, Sunami K, Matsumoto M, Shimizu K, et al. | Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma. | Acta Haematol | 144(3) | 264-274 | 2021 |
| Chari A, Rodriguez-Otero P, McCarthy H, Suzuki K, Touzeau C, et al. | Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. | Br J Haematol | 192(5) | 869-878 | 2021 |
| Luo MM, Usmani SZ, Mateos MV, Suzuki K, Parasrampur DA, et al. | Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. | J Clin Pharmacol | 61(5) | 614-627 | 2021 |
| Takezako N, Shibayama H, Suzuki K, Iida S, et al. | Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR. | Int J Hematol | 113(2) | 219-230 | 2021 |
| Sato K, Okazuka K, Ishida T, Sakamoto J, Kaneko S, Nashimoto J, Uto Y, Ogura M, Yoshiki Y, Abe Y, Maeda A, Hamazaki H, Tsukada N, Hiragohri Y, Suzuki K | Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry. | Ann Hematol | 100(12) | 2989-2995 | 2021 |
| Suzuki K, et al. | Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial. | Int J Hematol | 114(6) | 653-663 | 2021 |
| Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, et al. | Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. | Clin Lymphoma Myeloma Leuk | 21(11) | 785-798 | 2021 |
| Kimura K, Tsukamoto S, Miyazaki K, Kawajiri-Manako C, Ishii A, Rahmutulla B, Fukuyo M, Oshima-Hasegawa N, Mitsukawa S, Takeda Y, | Identification of clonal immunoglobulin λ light-chain gene rearrangements in AL amyloidosis using next-generation sequencing. | Exp Hematol | 101-102 | 34-41.e4 | 2021 |

| | | | | | |
|--|--|------------------------------|--------|---------|------|
| Mimura N, Takeuchi M, Ohwada C, Iseki T, Matsusaka K, Sanada M, Yokote K, Kaneda A, Ishida T, Suzuki K, et al. | | | | | |
| Fujimoto Y, Ueno S, Oda K, Gunda N, Shimomura Y, Nishimura Y, Yamaguchi A, Kuwano A, Ito Y, Baba Y, Nishigaki A, Michiwaki N, Uchino S, Kurogi K, Kawano Y, Matsuoka M, Saito H, Okuno Y, Jono H | Relationship between serum bortezomib concentration and emergence of diarrhea in patients with multiple myeloma and/or AL amyloidosis. | Cancers | 13(22) | 5674 | 2021 |
| Shirai N, Yamamoto S, Osawa Y, Tsubaki A, Morishita S, Nitami S, Narita I | Comparison of muscle strength between hemodialysis patients and non-dialysis patients with chronic kidney disease. | J Phys Ther Sci | 33(10) | 742-747 | 2021 |
| Shirai N, Yamamoto S, Osawa Y, Tsubaki A, Morishita S, Nitami S, Narita I | Fear of falling and physical activity in hemodialysis patients: a pilot study. | Renal Replace Ther | 7 | 63 | 2021 |
| Kitabayashi K, Yamamoto S, Katano Y, Giustini K, Ei I, Ishii Y, Narita I | Locomotive Syndrome in Hemodialysis Patients and its Association with Quality of Life – A Cross-Sectional Study – | Renal Replace Ther | 7 | 36 | 2021 |
| Yamamoto S, Sasahara K, Domon M, Yamaguchi K, Ito T, Goto S, Goto Y, Narita I | pH-Dependent Protein Binding Properties of Uremic Toxins In Vitro. | Toxins (Basel) | 13(2) | 116 | 2021 |
| Komaba H, Zhao J, Yamamoto S, Nomura T, Fuller DS, McCullough KP, Evenepoel P, Christensson A, Zhao X, Alrukhaimi M, Al-Ali F, Young EW, Robinson BM, Fukagawa M | Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS. | J Cachexia Sarcopenia Muscle | 12(4) | 855-865 | 2021 |
| Wakamatsu T, Iwasaki Y, Yamamoto S, Matsuo K, Goto S, Narita I, Kazama JJ, Tanaka K, Ito A, Ozasa R, Nakano T, Miyakoshi C, Onishi Y, Fukuma S, Fukuhara S, Yamato H, Fukagawa M, Akizawa T | Type I Angiotensin II Receptor Blockade Reduces Uremia-Induced Deterioration of Bone Material Properties. | J Bone Miner Res | 36(1) | 67-79 | 2021 |
| Sakai K, Yamada M | Cerebral amyloid angiopathy-related inflammation and dementia. | Clin Exp Neuroimmunol | 12 | 101-106 | 2021 |

| | | | | | |
|---|---|-----------------------|----|---------|------|
| Yamaguchi H, Kawahara H, Kodera N, Kumaki A, Tada Y, Sakai K, Ono K, Yamada M, Hanayama R | Extracellular vesicles contribute to the metabolism of transthyretin amyloid in hereditary transthyretin amyloidosis. | Front Mol Biosci | 9 | 839917 | 2022 |
| 坂井 健二, 濱口 毅, 山田 正仁 | 臨床医のための神経病理再入門 脳アミロイドアンギオパチー. | Clinical Neuroscience | 39 | 132-134 | 2021 |
| 坂井 健二, 山田 正仁 | 脳アミロイドアンギオパチー関連 炎症・血管炎. | BRAIN NERVE | 73 | 489-495 | 2021 |